Publication:
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

Simple item page
dc.contributor.authorSoto, Jorge
dc.contributor.authorMelo, Felipe
dc.contributor.authorGutierrez, Cristián
dc.contributor.authorSchultz, Bárbara
dc.contributor.authorBerríos, Roslye
dc.contributor.authorRivera, Daniela
dc.contributor.authorPiña, Alejandro
dc.contributor.authorHoppe, Guillermo
dc.contributor.authorDuarte, Luisa
dc.contributor.authorVázquez, Yaneisi
dc.contributor.authorMoreno, Daniela
dc.contributor.authorRíos, Mariana
dc.contributor.authorPalacios, Pablo
dc.contributor.authorGarcia, Richard
dc.contributor.authorSantibañez, Álvaro
dc.contributor.authorPacheco, Gaspar
dc.contributor.authorMendez, Constanza
dc.contributor.authorAndrade, Catalina
dc.contributor.authorSilva, Pedro
dc.contributor.authorDiethelm, Benjamín
dc.contributor.authorAstudillo, Patricio
dc.contributor.authorCalvo, Mario
dc.contributor.authorCárdenas, Antonio
dc.contributor.authorGonzález, Marcela
dc.contributor.authorGoldsack, Macarena
dc.contributor.authorGutiérrez, Valentina
dc.contributor.authorPotin, Marcela
dc.contributor.authorSchilling, Andrea
dc.contributor.authorTapia, Lorena
dc.contributor.authorTwele, Loreto
dc.contributor.authorVillena, Rodolfo
dc.contributor.authorGrifoni, Alba
dc.contributor.authorSette, Alessandro
dc.contributor.authorWeiskopf, Daniela
dc.contributor.authorFasce, Rodrigo
dc.contributor.authorFernández, Jorge
dc.contributor.authorMora, Judith
dc.contributor.authorRamírez, Eugenio
dc.contributor.authorGaete, Aracelly
dc.contributor.authorAcevedo, Mónica
dc.contributor.authorValiente, Fernando
dc.contributor.authorSoto, Ricardo
dc.contributor.authorRetamal, Angello
dc.contributor.authorMuñoz, Nathalia
dc.contributor.authorPedCoronaVac03CL Study Group
dc.contributor.authorMeng, Xing
dc.contributor.authorXin, Qianqian
dc.contributor.authorAlarcón, Eduardo
dc.contributor.authorGonzález, José
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorÁlvarez, María
dc.contributor.authorGonzález, Pablo
dc.contributor.authorAbarca, Katia
dc.contributor.authorPerret, Cecilia
dc.contributor.authorCarreño, Leandro
dc.contributor.authorBueno, Susan
dc.contributor.authorKalergisa, Alexis
dc.date.accessioned2023-05-05T14:54:26Z
dc.date.available2023-05-05T14:54:26Z
dc.date.issued2022
dc.description.abstractMultiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4+ T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD4+ T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD4+ T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials.gov under no. NCT04992260.) IMPORTANCE This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD4+ T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron.
dc.identifier.citationSoto JA, Melo-González F, Gutierrez-Vera C, Schultz BM, Berríos-Rojas RV, Rivera-Pérez D, Piña-Iturbe A, Hoppe-Elsholz G, Duarte LF, Vázquez Y, Moreno-Tapia D, Ríos M, Palacios PA, Garcia-Betancourt R, Santibañez Á, Pacheco GA, Mendez C, Andrade CA, Silva PH, Diethelm-Varela B, Astudillo P, Calvo M, Cárdenas A, González M, Goldsack M, Gutiérrez V, Potin M, Schilling A, Tapia LI, Twele L, Villena R, Grifoni A, Sette A, Weiskopf D, Fasce RA, Fernández J, Mora J, Ramírez E, Gaete-Argel A, Acevedo ML, Valiente-Echeverría F, Soto-Rifo R, Retamal-Díaz A, Muñoz-Jofré N; PedCoronaVac03CL Study Group,; Meng X, Xin Q, Alarcón-Bustamante E, González-Aramundiz JV, Le Corre N, Álvarez-Figueroa MJ, González PA, Abarca K, Perret C, Carreño LJ, Bueno SM, Kalergis AM. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children. mBio. 2022 Dec 20;13(6):e0131122. doi: 10.1128/mbio.01311-22
dc.identifier.doihttps://doi.org/10.1128/mbio.01311-22
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7464
dc.language.isoen
dc.subjectCOVID-19
dc.subjectCoronaVac,
dc.subjectPhase 3 clinical trial
dc.subjectPediatric
dc.subjectSARS-CoV-2
dc.subjectVaccines
dc.subjectVariants of concern
dc.subjectImmunogenicity
dc.subjectSafety
dc.titleInactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourcemBio
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific.pdf
Size:
2.4 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services